Literature DB >> 26115628

Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.

Joan Albert Barberà1, Isabel Blanco.   

Abstract

Pulmonary hypertension (PH) is a common complication of chronic pulmonary diseases, especially in advanced disease, and is associated with greater mortality and worse clinical course. Patients with symptoms that exceed those expected by their pulmonary disease should be further evaluated by echocardiography. Confirmatory right heart catheterization is indicated in those conditions where the results of the hemodynamic assessment will determine treatment options. The treatment of choice for patients who are hypoxemic and have pulmonary hypertension associated with chronic lung disease is long-term oxygen therapy. Conventional vasodilators or drugs approved for pulmonary arterial hypertension are not recommended in patients with mild-to-moderate PH because they may impair gas exchange and because there is a lack of evidence supporting their efficacy. Patients with severe PH should be considered for referral to a center with expertise in PH and lung diseases. Ideally, these patients should be included in randomized controlled trials to determine which patients are more likely to derive benefit and which therapies are most likely to be successful.

Entities:  

Mesh:

Year:  2015        PMID: 26115628     DOI: 10.1007/s11906-015-0574-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  83 in total

1.  Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease.

Authors:  N Roger; J A Barberà; J Roca; I Rovira; F P Gómez; R Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

2.  Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers.

Authors:  J A Barberà; V I Peinado; S Santos; J Ramirez; J Roca; R Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

3.  Echocardiographic Detection of Occult Cor Pulmonale During Exercise in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Masahiro Takakura; Takashi Harada; Hiroshi Fukuno; Hidesato Okushi; Tetsuzo Taniguchi; Seizo Sawada; Hiroyuki Fujinaga; Tetsuzo Wakatsuki; Takashi Oki
Journal:  Echocardiography       Date:  1999-02       Impact factor: 1.724

4.  Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease.

Authors:  Salud Santos; Victor I Peinado; Josep Ramirez; Jaime Morales-Blanhir; Ricardo Bastos; Josep Roca; Robert Rodriguez-Roisin; Joan A Barbera
Journal:  Am J Respir Crit Care Med       Date:  2003-02-20       Impact factor: 21.405

5.  Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.

Authors:  Ganesh Raghu; Rachel Million-Rousseau; Adele Morganti; Loyc Perchenet; Juergen Behr
Journal:  Eur Respir J       Date:  2013-05-16       Impact factor: 16.671

6.  Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Oksana A Shlobin; Shahzad Ahmad; Jim Koch; Scott D Barnett; Niv Ad; Nelson Burton; Kevin Leslie
Journal:  Respiration       Date:  2008-01-24       Impact factor: 3.580

7.  Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant.

Authors:  A F Shorr; J L Wainright; C S Cors; C J Lettieri; S D Nathan
Journal:  Eur Respir J       Date:  2007-07-11       Impact factor: 16.671

8.  Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Authors:  Ganesh Raghu; Juergen Behr; Kevin K Brown; Jim J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Steven D Nathan; Athol U Wells; Harold R Collard; Ulrich Costabel; Luca Richeldi; Joao de Andrade; Nasreen Khalil; Lake D Morrison; David J Lederer; Lixin Shao; Xiaoming Li; Patty S Pedersen; A Bruce Montgomery; Jason W Chien; Thomas G O'Riordan
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

9.  A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD.

Authors:  S L Archer; D Mike; J Crow; W Long; E K Weir
Journal:  Chest       Date:  1996-03       Impact factor: 9.410

10.  Pulmonary hemodynamic profile in chronic obstructive pulmonary disease.

Authors:  Karina Portillo; Yolanda Torralba; Isabel Blanco; Felip Burgos; Roberto Rodriguez-Roisin; Jose Rios; Josep Roca; Joan A Barberà
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-14
View more
  5 in total

Review 1.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

2.  A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study.

Authors:  Rong Jiang; Cheng Wu; Bigyan Pudasaini; Lan Wang; Qin-Hua Zhao; Rui Zhang; Wen-Hui Wu; Ping Yuan; Zhi-Cheng Jing; Jin-Ming Liu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-06-14

Review 3.  Assessing pulmonary hypertension in COPD. Is there a role for computed tomography?

Authors:  Florence Coste; Ilyes Benlala; François Laurent; Patrick Berger; Gaël Dournes; Pierre-Olivier Girodet
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-09-04

4.  Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease.

Authors:  Kurt W Prins; Lauren Rose; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Matthew D Olson; Thenappan Thenappan
Journal:  J Am Heart Assoc       Date:  2019-01-22       Impact factor: 5.501

5.  Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension.

Authors:  Rong Jiang; Lan Wang; Qin-Hua Zhao; Cheng Wu; Ping Yuan; Shang Wang; Rui Zhang; Su-Gang Gong; Wen-Hui Wu; Jing He; Hong-Ling Qiu; Ci-Jun Luo; Jin-Ming Liu; Zhi-Cheng Jing
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.